Hojnik Marko, Frković Grazio Snježana, Verdenik Ivan, Rižner Tea Lanišnik
Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Division of Gynecology, Department of Pathology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
Cancers (Basel). 2021 Jul 7;13(14):3398. doi: 10.3390/cancers13143398.
The roles of aldo-keto reductase family 1 member B1 (AKR1B1) and B10 (AKR1B10) in the pathogenesis of many cancers have been widely reported but only briefly studied in endometrial cancer. To clarify the potential of AKR1B1 and AKR1B10 as tissue biomarkers of endometrial cancer, we evaluated the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 101 well-characterized patients with endometrioid endometrial cancer and 12 patients with serous endometrial cancer and compared them with the clinicopathological data. Significantly higher immunohistochemical levels of AKR1B1 and AKR1B10 were found in adjacent non-neoplastic endometrial tissue compared to endometrioid endometrial cancer. A trend for better survival was observed in patients with higher immunohistochemical AKR1B1 and AKR1B10 levels. However, no statistically significant differences in overall survival or disease-free survival were observed when AKR1B1 or AKR1B10 were examined individually in endometrioid endometrial cancer. However, analysis of AKR1B1 and AKR1B10 together revealed significantly better overall and disease-free survival in patients with both AKR1B1 and AKR1B10 staining above the median values compared to all other patients. Multivariant Cox analysis identified strong AKR1B1 and AKR1B10 staining as a statistically important survival prediction factor. Conversely, no significant differences were found in serous endometrial cancer. Our results suggest that AKR1B1 and AKR1B10 play protective roles in endometrioid endometrial cancer and show potential as prognostic biomarkers.
醛酮还原酶家族1成员B1（AKR1B1）和B10（AKR1B10）在多种癌症发病机制中的作用已得到广泛报道，但在子宫内膜癌中的研究较少。为了阐明AKR1B1和AKR1B10作为子宫内膜癌组织生物标志物的潜力，我们评估了101例特征明确的子宫内膜样子宫内膜癌患者和12例浆液性子宫内膜癌患者组织石蜡切片中AKR1B1和AKR1B10的免疫组化水平，并将其与临床病理数据进行比较。与子宫内膜样子宫内膜癌相比，在相邻的非肿瘤性子宫内膜组织中发现AKR1B1和AKR1B10的免疫组化水平显著更高。免疫组化AKR1B1和AKR1B10水平较高的患者观察到有更好的生存趋势。然而，在子宫内膜样子宫内膜癌中单独检测AKR1B1或AKR1B10时，总生存期或无病生存期没有统计学上的显著差异。然而，对AKR1B1和AKR1B10一起分析发现，与所有其他患者相比，AKR1B1和AKR1B10染色均高于中位数的患者的总生存期和无病生存期显著更好。多变量Cox分析确定AKR1B1和AKR1B10强染色是一个具有统计学意义的生存预测因素。相反，在浆液性子宫内膜癌中未发现显著差异。我们的结果表明，AKR1B1和AKR1B10在子宫内膜样子宫内膜癌中起保护作用，并显示出作为预后生物标志物的潜力。
